Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

Giovanni PalladiniAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, ItalyCorrespondence[email protected]

Paolo MilaniAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Marco BassetAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Francesca RussoAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Francesca LavatelliAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Mario NuvoloneAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Giovanni FerraroAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Margherita BozzolaAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Andrea FoliAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Stefano PerliniAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

Giampaolo MerliniAmyloidosis Research and Treatment Center, Foundation (IRCCS) Policlinico San Matteo, Pavia, Italy and ;Department of Molecular Medicine, University of Pavia, Pavia, Italy

show all

References

Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016;128:159–68.
PubMed Web of Science ®Google Scholar
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–9.
PubMed Web of Science ®Google Scholar
Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881–7.
PubMed Web of Science ®Google Scholar
Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, Foli A, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 2013;121:3420–7.
PubMed Web of Science ®Google Scholar
Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, Vidus Rosin M, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 2014;124:2325–32.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date